https://www.selleckchem.com/pr....oducts/alw-ii-41-27.
The benchmarking process has to be implemented among health care providers for individuals with DSD within the European Reference Networks for Rare Conditions.This study aimed to investigate the mechanism of type I interferon (IFN) in aggravating sepsis in bacterial infection, focusing on the roles of Caspase-11 (Casp11) and Gasdermin D (Gsdmd) in this process. Type I interferons, including IFNα and IFNβ, were used to treat peritoneal macrophage harvested from wild-type or IFNα/βR1 knockout (KO) mice, of which the levels of Casp11
Like
Comment
Share
